Venus Concept Stock Price, News & Analysis

Venus Concept Inc. (NASDAQ: VERO) is a medical technology company in the surgical appliance and supplies manufacturing industry that focuses on medical aesthetic and hair restoration technologies. According to company disclosures, Venus Concept describes itself as a global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive systems used for body, face, skin and hair-related treatments. The company’s common stock is listed on The Nasdaq Capital Market under the symbol VERO.

Venus Concept’s business centers on the development, commercialization and delivery of aesthetic device platforms and hair restoration systems. Its aesthetic platforms, as described in multiple company press releases, include branded systems such as Venus NOVA, Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Viva MD, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve and AI.ME. For hair restoration, the company’s portfolio has included NeoGraft and the ARTAS iX Robotic Hair Restoration system. These technologies are used in medical aesthetic practices for applications that the company associates with body contouring, muscle conditioning, skin treatments, and hair restoration procedures.

Business focus and product portfolio

In its public communications, Venus Concept states that it offers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company reports that its aesthetic platforms are designed for treatments involving the body, face and skin, while its hair restoration systems are used in hair transplant and related procedures. The firm’s product family includes multi-application platforms and dedicated systems that are sold as devices, along with related products and services.

The company has highlighted a significant new platform, Venus NOVA, which received U.S. Food and Drug Administration (FDA) 510(k) clearance to be marketed as a next-generation, multi-application platform for non-invasive body, face and skin treatments. In its description of Venus NOVA, Venus Concept notes that the system integrates Adaptive Electrical Muscle Stimulation (EMS), its proprietary (MP)² technology (combining Multi-Polar Radio Frequency with Pulsed Electromagnetic Fields), and Advanced VariPulse technology. The company states that this combination is intended to support body contouring, muscle conditioning, skin treatments, and wrinkle and cellulite reduction.

Venus Concept also describes a digital layer around its devices. For example, Venus NOVA is said to include IoT connectivity through Venus Connect, a secure cloud-based application that provides real-time analytics, treatment insights and automatic system optimization. The company positions this connectivity as a way for clinics to monitor device performance and access data-driven insights. In addition, the firm refers to the Venus Jumpstart Program, a 30-day roadmap that includes clinical education, marketing enablement and implementation support to help practices integrate Venus NOVA into their operations.

Hair restoration and strategic portfolio changes

Venus Concept’s hair restoration offerings have included the NeoGraft system and the ARTAS iX Robotic Hair Restoration system, which the company groups under its Venus Hair business. In a June 2025 announcement, Venus Concept disclosed that it had entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd. (Meta Healthcare Group) in an all-cash transaction valued at $20 million, subject to customary adjustments. Under that agreement, Meta Healthcare Group would acquire a newly formed subsidiary, Meta Robotics LLC, containing the company’s portfolio of hair restoration and hair transplant technologies, related equipment, services and assets, including intellectual property relating to ARTAS and NeoGraft.

Venus Concept stated that this planned divestiture is part of its evaluation of strategic alternatives and that it expects the transaction, once completed, to allow the company to focus on its global medical aesthetics business. The company has indicated that concentrating on medical aesthetics is expected, from its perspective, to improve revenue growth, lower operating expenses, enhance the cash flow profile of the business and support a path toward longer-term profitability. As of the most recent updates provided, the company has also reported challenges in closing the Venus Hair transaction and has noted that it sought assistance from the Delaware Court of Chancery in connection with that process.

Revenue model and geographic reach

Venus Concept’s public financial disclosures describe revenue generated from leases, products and services. The company breaks out revenue by product category into Venus Prime / subscription systems, products – systems, products – other, and services. It also reports revenue by region, distinguishing between the United States and International markets. In its quarterly results, the company has discussed trends such as changes in U.S. revenue, international revenue, and the share of total systems revenue derived from internal lease programs (Venus Prime and a legacy subscription model).

According to company descriptions in recent press releases, Venus Concept’s technologies have reach in over 60 countries and 9 direct markets. The company positions itself as having a global footprint in medical aesthetics, although the detailed breakdown of countries is not provided in the supplied materials. The firm has also stated that it has been backed by several healthcare-focused growth equity investors, including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, Masters Special Situations and Madryn Asset Management.

Capital structure, financing and strategic transactions

Venus Concept’s SEC filings and press releases describe a period of active capital structure management. The company has disclosed multiple bridge loan drawdowns under a Loan and Security Agreement with affiliates of Madryn Health Partners, as well as a series of Consent Agreements and Bridge Loan Amendments that extend maturity dates and waive certain minimum liquidity requirements for specified periods. These arrangements involve Venus Concept Inc. and several wholly owned subsidiaries as loan parties, with Madryn and related entities as lenders and administrative agent.

In addition, the company has reported debt-to-equity exchange transactions in which subordinated convertible notes held by Madryn affiliates were exchanged for shares of Series Y Convertible Preferred Stock. For example, Venus Concept announced exchanges of subordinated convertible notes into Series Y preferred shares on June 30, 2025 and September 30, 2025, and noted that these exchanges reduced total debt obligations compared to prior periods. The company has also amended the certificate of designations for its Series Y Preferred Stock multiple times, including increasing the authorized shares and eliminating provisions for automatic conversion into common stock.

Beyond debt exchanges, Venus Concept has conducted registered direct offerings of common stock priced at-the-market under Nasdaq rules, along with concurrent private placements of unregistered short-term warrants. The company has stated that it intends to use net proceeds from these offerings for general corporate purposes. Its filings also refer to an ongoing evaluation of strategic alternatives to maximize shareholder value, including the proposed sale of the Venus Hair business and potential other transactions.

Operational and financial context

In its quarterly financial results, Venus Concept has discussed changes in revenue, gross profit, operating expenses and operating loss. The company has attributed certain revenue and margin trends to factors such as customer uncertainty about the economic environment, tighter third-party lending practices affecting capital equipment sales, tariffs on devices imported into the U.S. market, and supply disruptions related to geopolitical events affecting a contract manufacturer’s facility. It has also referenced efforts in cost containment and streamlining of operations, noting modest changes in operating expenses year over year.

The company has reported that its Energy Based Device (EBD) revenues, excluding ARTAS and NeoGraft, have shown signs of stabilization in recent periods. At the same time, Venus Concept has acknowledged declines in its hair restoration business revenue, which it links to the pending sale of the Venus Hair business and associated customer uncertainty. The firm has also indicated that it is in active dialogue with lenders and investors and is not providing financial guidance for certain periods due to ongoing evaluations of strategic alternatives and potential trade disruptions.

Regulatory and listing status

Venus Concept’s SEC filings show that its common stock trades on The Nasdaq Capital Market under the symbol VERO. The filings provided include multiple Current Reports on Form 8-K covering material definitive agreements, financing transactions, amendments to preferred stock designations, and the reporting of quarterly financial results. The materials do not include any Form 25 or Form 15 filings or explicit statements indicating that the company has been delisted or deregistered. Based on the supplied information, Venus Concept continues to report as a Nasdaq-listed issuer.

Investor considerations

Investors reviewing Venus Concept typically examine the company’s product portfolio in medical aesthetics and hair restoration, its global reach, and its capital structure. The firm’s disclosures highlight ongoing efforts to manage debt levels through exchanges and amendments, raise equity capital, and pursue strategic transactions such as the proposed divestiture of the Venus Hair business. At the same time, the company’s financial results reflect operating losses, changes in revenue by region and product category, and sensitivity to macroeconomic and financing conditions in the aesthetics market.

According to its own statements, Venus Concept aims to align its research and development and product roadmap with a focused R&D strategy and a Venus AI strategic initiative, as reflected in the development and clearance of Venus NOVA. The company presents this as part of a broader turnaround plan that includes product innovation, portfolio optimization, and capital structure adjustments, supported by financing relationships with Madryn Asset Management and other investors.

Frequently Asked Questions

• What does Venus Concept Inc. do?
  Venus Concept Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. Its portfolio includes aesthetic device platforms for body, face and skin treatments, as well as hair restoration systems such as NeoGraft and the ARTAS iX Robotic Hair Restoration system, as described in the company’s public disclosures.
• What industry and sector is Venus Concept in?
  Venus Concept operates in the surgical appliance and supplies manufacturing industry within the broader manufacturing sector, with a focus on medical aesthetic technology and hair restoration devices.
• Which products are part of Venus Concept’s aesthetic device portfolio?
  According to company press releases, Venus Concept’s aesthetic device platforms include Venus NOVA, Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Viva MD, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve and AI.ME. These systems are used in medical aesthetic practices for body, face and skin applications.
• What is the Venus Hair business?
  The Venus Hair business comprises Venus Concept’s hair restoration and hair transplant technologies, including NeoGraft and the ARTAS iX Robotic Hair Restoration system, along with related equipment, services and intellectual property. The company has entered into a definitive agreement to sell this business to MHG Co. Ltd., subject to closing conditions.
• Has Venus Concept agreed to sell its hair restoration business?
  Yes. In June 2025, Venus Concept announced a definitive agreement to sell its Venus Hair business to MHG Co. Ltd. in an all-cash transaction valued at $20 million, subject to customary working capital adjustments and other closing conditions. The company has subsequently reported challenges with the counterparty in closing this transaction and has sought assistance from the Delaware Court of Chancery.
• How does Venus Concept generate revenue?
  In its financial statements, Venus Concept reports revenue from leases and from products and services. It further categorizes revenue into Venus Prime / subscription systems, products – systems, products – other, and services, and reports revenue by region for the United States and International markets.
• What is Venus NOVA?
  Venus NOVA is described by the company as its next-generation, multi-application platform for non-invasive treatments for the body, face and skin. It integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² technology combining Multi-Polar RF and Pulsed Electromagnetic Fields, and Advanced VariPulse technology. Venus NOVA also features IoT connectivity through Venus Connect and is supported by the Venus Jumpstart Program.
• Where does Venus Concept operate?
  Venus Concept states that it has reach in over 60 countries and 9 direct markets. The provided materials do not list all specific countries, but the company characterizes itself as a global medical aesthetic technology business.
• Who are some of Venus Concept’s investors and lenders?
  The company reports backing from healthcare-focused growth equity investors such as EW Healthcare Partners, HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, Masters Special Situations and Madryn Asset Management. Affiliates of Madryn also serve as lenders and administrative agent under Venus Concept’s Main Street Priority Loan and Bridge Loan facilities.
• Is Venus Concept still listed on Nasdaq?
  Based on the supplied SEC filings, Venus Concept’s common stock is registered under Section 12(b) of the Securities Exchange Act and trades on The Nasdaq Capital Market under the symbol VERO. No delisting or deregistration filings are included in the provided information.